Electronic Acknowledgement Receipt				
EFS ID:	6762427			
Application Number:	10848820			
International Application Number:				
Confirmation Number:	4787			
Title of Invention:	Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure			
First Named Inventor/Applicant Name:	Timothy A. McKinsey			
Customer Number:	32425			
Filer:	Steven Lee Highlander/Steven L. Highlander			
Filer Authorized By:	Steven Lee Highlander			
Attorney Docket Number:	MYOG:044US/10405748			
Receipt Date:	06-JAN-2010			
Filing Date:	19-MAY-2004			
Time Stamp:	17:38:50			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$1110
RAM confirmation Number	4028
Deposit Account	501212
Authorized User	HIGHLANDER,STEVEN L.

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			
1		MYOG044US_AMEND.pdf	505623	yes	12			
	MTOGO4403_AMEND.pdf	00df6d48fa1a2b5cfda8eda3b432c6f3677f7 e3f	yes					
	Multipart Description/PDF files in .zip description							
	Document Description		Start	End				
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1				
	Claims		2	3				
	Applicant Arguments/Remarks Made in an Amendment		4	12				
Warnings:								
Information:								
2 Extension of Time	MYOG044US_EOT.pdf	62614	no	1				
		003e1b726b33dec0be38566e74080c59290 a82ff						
Warnings:								
Information:								
3 Fee Worksheet (PTO-875)	fee-info.pdf	30561	no	2				
		617a76166d1f92cf8d25a3b05cd43962c840 b5ad						
Warnings:								
Information:								
		Total Files Size (in bytes)	59	98798				

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.